DEVELOPING IN SILICO TRIALS TO FIGHT TUBERCULOSIS
Tuberculosis is one of the world’s deadliest diseases:
it infects one third of the world’s population in developing countries and the high costs, long duration and poor compliance with the therapy, may lead to the development of multi-drug resistant bacterial strains, that make much harder to eradicate this disease.
STRITUVAD project aims to develop computer simulations to test the efficacy of new therapies, significantly reducing costs and duration of human clinical trials.
PATIENTS & PUBLIC
Last year over 1.6 million people worldwide died of Tuberculosis. We need better therapies, but the current process of development would make them too expensive for most developing economies. Here we explain in simple words how In Silico Trials technologies could help.
There is a huge potential around the possibility to design therapeutic vaccines for Tuberculosis that work in conjunction with conventional cures. But there are infinite combinations: how can we test them clinically, while keeping the costs at reasonable levels?
In lower income countries the game is affordable cures; in developed countries is the long-term sustainability of universal healthcare systems. Across the world, for different reasons, pharma industries need to cut down drug development and clinical assessment costs. Can computers help?
The STriTuVaD project aims to develop and clinically validate an in silico trials technology capable of predicting the efficacy of therapies for active tuberculosis based on innovative therapeutic vaccines. This could open the road to a future regulatory qualification.
STriTuVaD is a project funded by the Horizon 2020 EU Research and Innovation programme and by the Department of BioTechnology of the Government of India